Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent ...
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved ...
Food & Wine / Getty Images Arsenic has repeatedly made headlines over the past year ... Arsenic can also cause short-term symptoms, including vomiting, abdominal pain, numbness and tingling, muscle ...